What SEC filings does Emergent BioSolutions Inc. submit to the SEC?

Emergent BioSolutions Inc. (EBS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about EBS?

A Form 4 for EBS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Emergent BioSolutions Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for EBS?

The 10-K is Emergent BioSolutions Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all EBS SEC filings directly on EDGAR?

You can view all historical Emergent BioSolutions Inc. filings on the SEC EDGAR company page for EBS. Each filing card on this page links directly to the original SEC document.

How often does Emergent BioSolutions Inc. file with the SEC?

Emergent BioSolutions Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling EBS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

EBS SEC Filing News — Emergent BioSolutions Inc.

Latest SEC filings for Emergent BioSolutions Inc. (EBS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul…

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $326.1M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for EBS currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

EBS Filing Activity Snapshot 2026-05-04 — 2026-10-16

Insider Transactions (Form 4)

0 buys vs 6 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$130.0K

DeGolyer Donald W (Director) · 2026-05-04

15,481 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Emergent BioSolutions Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 open-market sale, 4 tax withholding and 1 compensation award. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Tax withholding ×4: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Compensation award ×1: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Open-market sale Insider Selling 2026-10-07

EBS insider DeGolyer Donald W (Director) sold 17,800 shares (~$126.2K)

DeGolyer Donald W, listed as Director at Emergent BioSolutions Inc., reported an open-market sale of 17,800 EBS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	17,800	$7.09	$126.2K

Filing: Form 4 (Insider Transaction) Insider: DeGolyer Donald W (Director) Shares: 17,800 Est. Value: $126.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-05

EBS insider Williams Paul Anthony (SVP, Products Business) sold 3,000 shares (~$19.6K)

Williams Paul Anthony, listed as SVP, Products Business at Emergent BioSolutions Inc., reported an open-market sale of 3,000 EBS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,000	$6.53	$19.6K

Filing: Form 4 (Insider Transaction) Insider: Williams Paul Anthony (SVP, Products Business) Shares: 3,000 Est. Value: $19.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-02

EBS insider Williams Paul Anthony (SVP, Products Business) sold 3,000 shares (~$25.2K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,000	$8.40	$25.2K

Filing: Form 4 (Insider Transaction) Insider: Williams Paul Anthony (SVP, Products Business) Shares: 3,000 Est. Value: $25.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-06-10

EBS insider Form 4 filed for equity award, exercise, or tax withholding

Williams Paul Anthony (SVP, Products Business) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	694	$8.00	$5.6K

Filing: Form 4 (Insider Transaction) Insider: Williams Paul Anthony (SVP, Products Business) Shares: 694

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-06-10

EBS insider Form 4 filed for equity award, exercise, or tax withholding

LINDAHL RICHARD S (EVP, Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	3,964	$8.00	$31.7K

Filing: Form 4 (Insider Transaction) Insider: LINDAHL RICHARD S (EVP, Chief Financial Officer) Shares: 3,964

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-06-10

EBS insider Form 4 filed for equity award, exercise, or tax withholding

Glessner Coleen (EVP, Quality & Ethics, and CPL) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	2,018	$8.00	$16.1K

Filing: Form 4 (Insider Transaction) Insider: Glessner Coleen (EVP, Quality & Ethics, and CPL) Shares: 2,018

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-06-10

EBS insider Form 4 filed for equity award, exercise, or tax withholding

Hartzel William (SVP, Bioservices) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	1,741	$8.00	$13.9K

Filing: Form 4 (Insider Transaction) Insider: Hartzel William (SVP, Bioservices) Shares: 1,741

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-05-04

EBS insider Dayal Sujata Tyagi (Director) sold 13,761 shares (~$115.6K)

Dayal Sujata Tyagi, listed as Director at Emergent BioSolutions Inc., reported an open-market sale of 13,761 EBS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,344	—	—
`S`	Open-market sale	12,781	$8.36	$106.8K
`S`	Open-market sale	980	$8.94	$8.8K
`A`	Compensation award derivative · Stock Option (Right to Buy)	11,296	—	—

Filing: Form 4 (Insider Transaction) Insider: Dayal Sujata Tyagi (Director) Shares: 13,761 Est. Value: $115.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-05-04

EBS insider DeGolyer Donald W (Director) sold 15,481 shares (~$130.0K)

DeGolyer Donald W, listed as Director at Emergent BioSolutions Inc., reported an open-market sale of 15,481 EBS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,344	—	—
`S`	Open-market sale	14,527	$8.36	$121.4K
`S`	Open-market sale	954	$8.96	$8.5K
`A`	Compensation award derivative · Stock Option (Right to Buy)	11,296	—	—

Filing: Form 4 (Insider Transaction) Insider: DeGolyer Donald W (Director) Shares: 15,481 Est. Value: $130.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-05-04

EBS insider Katkin Keith (Director) sold 15,481 shares (~$128.2K)

Katkin Keith, listed as Director at Emergent BioSolutions Inc., reported an open-market sale of 15,481 EBS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,344	—	—
`S`	Open-market sale	15,481	$8.28	$128.2K
`A`	Compensation award derivative · Stock Options (Right to Buy)	11,296	—	—

Filing: Form 4 (Insider Transaction) Insider: Katkin Keith (Director) Shares: 15,481 Est. Value: $128.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-04

EBS insider Form 4 filed for equity award, exercise, or tax withholding

White Marvin L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,344	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	11,296	—	—

Filing: Form 4 (Insider Transaction) Insider: White Marvin L (Director) Shares: 25,344

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Emergent BioSolutions Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-07

EBS Form 144 filed for proposed insider sale by DONALD DEGOLYER (17,800 shares) ~$126.1K

DONALD DEGOLYER filed a Form 144 with the SEC indicating intent to sell EBS (Emergent BioSolutions Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: DONALD DEGOLYER Shares: 17,800 Est. Value: $126.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-10-01

EBS Form 144 filed for proposed insider sale by PAUL WILLIAMS (3,000 shares) ~$19.6K

PAUL WILLIAMS filed a Form 144 with the SEC indicating intent to sell EBS (Emergent BioSolutions Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PAUL WILLIAMS Shares: 3,000 Est. Value: $19.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-01

EBS Form 144 filed for proposed insider sale by PAUL WILLIAMS (3,000 shares) ~$25.2K

Filing: Form 144 (Proposed Sale Notice) Insider: PAUL WILLIAMS Shares: 3,000 Est. Value: $25.2K

View on SEC EDGAR → Open Filing Document →

Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Emergent BioSolutions Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-16

EBS filed 8-K — material company event

Emergent BioSolutions Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-14

EBS filed 8-K — material company event

Emergent BioSolutions Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-01

EBS filed 8-K — material company event

Emergent BioSolutions Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-05

EBS filed 8-K — material company event

Emergent BioSolutions Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-29

EBS filed 8-K — material company event

Emergent BioSolutions Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Emergent BioSolutions Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

EBS filed Quarterly Report (10-Q)

Emergent BioSolutions Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Emergent BioSolutions Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on EBS. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — EBS SEC Filings

More Tools for EBS

EBS Full Stock Analysis EBS Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper EBS analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the EBS stock analysis page.

EBS Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer